BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會


Andrea Wijeweera

Session 6 – Pandemic Control after Vaccination (B)

Date:22 July (Thursday)
Time: 10:40 – 12:10 (GMT+8)

Andrea Wijeweera

APAC Product Manager
Roche Diagnostics Asia Pacific Pte Ltd



Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, anti-malarials and cancer medicines. Roche has been recognized as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit:


Speech title & Synopsis

COVID-19 Pandemic Management: The Value of Diagnostics

The COVID-19 pandemic has brought on unprecedented health and economic challenges worldwide. As part of the global response to COVID-19, the diagnostics industry has come together in an effort to provide critically needed tests for this disease. In order to effectively manage the disease, it is critical to understand which tests are most suitable to use in order to help reduce disease spread and understand disease prevalence. In this talk, we will be providing an overview of the various types of tests available, key features for reliable detection of infection and/or immunity and the potential use cases in our current setting as we head towards our new “normal”.